Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03889483
Other study ID # ACH-NCI-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 30, 2018
Est. completion date December 30, 2021

Study information

Verified date January 2021
Source Alberta Children's Hospital
Contact Michael Esser, MD
Phone (403) 955 -7911
Email Michael.Esser@albertahealthservices.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

EEG signals have been collected and studied since the early 1990's as a way of assessing brain function at a gross level. As early as the 1930's a derivative of the raw EEG signal - event-related potentials (ERPs) - have been computed. The current research is primarily focused on three ERP components: the N100, P300 and N400. Each of the three ERPs have been studied in the academic laboratory for multiple decades. Through this research, a strong understanding has been developed regarding what can affect these components (e.g. task set, emotional state, etc.). However, these signals within various pediatric populations (e.g., those with persistent mTBI symptoms or multiple concussions) are not well characterized. Being able to safely and effectively employ the NeuroCatch™ Platform in a post-concussive pediatric cohort could provide researchers with the potential to elucidate the persistence of objective measures of impairment, patterns of recovery, and chronicity of problems due to mTBI in children. Secondly, understanding the degree to which these neurophysiological components fluctuate over time is crucial to the understanding of brain functioning. However, for this type of technology to be useful in quantifying brain health in this population,the degree to which a post-concussive pediatric brain naturally fluctuates in its processing capability must be quantified. NeuroCatch™ Platform has the ability to measure changes in several domains of brain function. These cognitive processes are foundational blocks for some of the highest cognitive processes: information integration and executive functioning.


Recruitment information / eligibility

Status Recruiting
Enrollment 105
Est. completion date December 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: 1. Male, female, or intersex 2. 8-18 years old inclusively 3. Must meet all criteria in one of the following cohorts: 1. Cohort 1: Has persistent mTBI symptoms 6-16 weeks post-injury, as determined by the Investigator; 2. Cohort 2: Recovered quickly (within approximately six weeks) from mTBI, as determined by the Investigator 6-16 weeks post-injury; 3. Cohort 3: Has had multiple mTBIs (2 or more medically verified concussions over the last year) with the most recent injury having occurred 6-16 weeks prior to study enrollment; 4. Cohort 4: Has never had a concussion. Exclusion Criteria: 1. Previous neurological illnesses (e.g., epilepsy or seizure disorders) including moderate to severe learning difficulties, as determined by the Investigator 2. Clinically documented hearing issues (e.g., tinnitus, in-ear hearing problems, punctured ear drum) 3. In-ear hearing aid or cochlear implant, hearing devices 4. Implanted pacemaker 5. Metal or plastic implants in skull 6. Allergy to rubbing alcohol or EEG gel 7. Previous participation in one or more studies using the NeuroCatchTM Platform 8. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin) 9. Using other investigational drugs or devices while enrolled in this study 10. Not fluent in the English language 11. If female and of child-bearing potential: suspected or planning to become pregnant, currently pregnant, or breast-feeding

Study Design


Intervention

Device:
NeuroCatch™ Platform
The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.

Locations

Country Name City State
Canada Alberta Children's Hospital, Department of Paediatrics Calgary Alberta

Sponsors (2)

Lead Sponsor Collaborator
Dr. Michael Esser NeuroCatch Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Explore trends between select additional measures of impairment and ERPs across four pediatric cohorts. Additional measures of impairment may include cognitive assessments, blood work and DNA analysis, brain imaging (MRI) and levels of carbon dioxide in the breath. 1 day
Primary Tracking and comparison of neurophysiological changes (ERP response size) to persistence of mTBI symptoms Response size will be measured as amplitude in microvolts. Persistence of mTBI symptoms will be defined by cohort. 1 day
Primary Tracking and comparison of neurophysiological changes (ERP response timing) to persistence of mTBI symptoms Response timing will be measured as latency in milliseconds. Persistence of mTBI symptoms will be defined by cohort. 1 day
Secondary Number of adverse events and adverse device effects Assessing the safety and performance of the NeuroCatchTM Platform in four pediatric cohorts. 1 day
Secondary Collection of ERP response size (amplitude in microvolts) and response timing (latency in milliseconds) Quantifying the natural variability in selected ERPs (N100, P300, N400) acquired using the NeuroCatchTM Platform in one study session. 1 day
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1